CytoSorbents Corporation — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing; quarterly figures are summarized below. Amounts are U.S. dollars.
Business context
CytoSorbents develops and sells blood-purification devices, led by CytoSorb, an extracorporeal adsorber used in critical care and cardiac surgery. CytoSorb is CE-marked in Europe for cytokine removal and certain expanded uses; in the U.S., it had Emergency Use Authorization (EUA) for specified COVID-19 patients, but was not FDA-cleared or approved for that indication. The company reported use in more than 121,000 human treatments and sales or distribution arrangements in 67 countries.
Financial performance and liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Total revenue | $41.00 million | $24.95 million | +64% |
| Product sales | $39.45 million | $22.77 million | +73% |
| Gross profit | $29.95 million | $17.59 million | +70% |
| Gross margin, total revenue | 73.0% | 70.5% | +2.5 percentage points |
| Operating expenses | $40.32 million | $36.56 million | +10% |
| Operating loss | $(10.37) million | $(18.97) million | Loss narrowed |
| Net loss | $(7.84) million | $(19.27) million | Loss narrowed |
| Basic and diluted loss per share | $(0.20) | $(0.60) | Improved |
| Operating cash flow | $(5.61) million | $(16.76) million | Cash use declined |
| Cash and cash equivalents at year-end | $71.42 million | $12.23 million | +$59.19 million |
| Working capital at year-end | $72.30 million | $10.97 million | +$61.33 million |
Product gross margin was approximately 76% in 2020 versus 77% in 2019; management attributed the decline to a higher share of lower-margin distributor sales and costs of rapidly increasing production. Total gross margin above includes grant revenue. FY2020 cash used in operating and investing activities, the company’s stated cash-burn measure, was approximately $7.29 million.
The company had no term debt outstanding at December 31, 2020, after repaying its $15 million Bridge Bank loan. It retained access, at its discretion through December 4, 2021, to a new $15 million term-loan commitment. Total liabilities were $10.73 million and total stockholders’ equity was $79.22 million.
FY2020 financing included approximately $53.8 million net proceeds from a July public offering and $26.5 million net proceeds from at-the-market share sales. Shares outstanding rose to 43.22 million at year-end from 32.62 million a year earlier. Management said year-end cash was expected to fund operations well beyond the next 12 months.
Material changes and Q4 performance
- Growth was driven by higher direct and distributor sales. Direct sales increased approximately $8.9 million and distributor sales approximately $7.8 million year over year. Management estimated that about $9.4 million of FY2020 product sales related to COVID-19 demand; it cautioned that replacement of this revenue in 2021 was uncertain.
- U.S. sales under the COVID-19 EUA were approximately $1.34 million for the year. The filing separately notes the estimated COVID-related sales figure above; the figures represent different disclosures and should not be treated as identical measures.
- R&D expense fell 27% to $8.81 million, principally because COVID-related hospital restrictions paused or slowed company-sponsored trials. SG&A rose 29% to $28.46 million, reflecting higher staffing, commissions, royalties and stock-based compensation.
- A $2.61 million foreign-currency transaction gain, compared with a $0.35 million loss in 2019, contributed to the improvement in net loss. The stronger euro also supported reported sales.
- Q4 2020 revenue was $11.96 million, versus $7.43 million in Q4 2019, up approximately 61%. Q4 gross profit was $9.43 million; operating loss was $2.63 million and net loss was $0.68 million. Q4 2019 operating and net losses were $5.43 million and $3.95 million, respectively. Q4 2020 basic and diluted loss per share rounded to $0.00.
Outlook, risks and unusual items
- No formal revenue, earnings or margin guidance is provided. Management described liquidity as sufficient to fund operations and clinical-trial activity well into the future, while acknowledging that additional financing could be needed depending on sales, trial costs, regulatory progress, reimbursement and commercialization needs.
- Clinical and regulatory execution remains central. The pivotal U.S. REFRESH 2-AKI cardiac-surgery study had enrolled 153 patients before a pause; the company planned to resume it in the first half of 2021 and, if successful, expected to pursue a PMA submission in 2023. REMOVE topline results were expected in the first half of 2021, while COVID-19 affected TISORB and other trial activity. These were expectations stated in the filing, not outcomes.
- CytoSorb’s COVID-19 U.S. use was under a time-limited EUA, not full marketing approval. FDA approval for other U.S. uses remained subject to clinical evidence and regulatory review. The company also cited reimbursement uncertainty, dependence on Germany for a majority of product sales, manufacturing and supply risks, foreign-exchange exposure, competition, and patent protection—including near-term patent expirations.
- COVID-19 both supported demand and disrupted operations: it delayed clinical trials and grant work, and affected hospitals, suppliers and commercial activity. The company reported its manufacturing facilities remained operational.
- German customs authorities were reviewing the tariff classification of imported devices. The company disclosed maximum potential exposure of approximately $732,000, recorded no liability because management considered the contingency not probable, and expected the review to conclude around March 31, 2021.
- The company reported no current legal proceedings. It has a history of losses and an accumulated deficit of $196.63 million. Although the risk-factor text refers to substantial doubt about going concern, the financial-statement note says the July 2020 offering and $71.4 million year-end cash substantially mitigated going-concern risk; the independent auditor’s opinion in the supplied filing text is unqualified.
Most important facts for investors to verify
- Whether COVID-related sales—estimated by management at $9.4 million in 2020—persisted or were replaced after the pandemic-related demand surge.
- Subsequent results and enrollment progress for REFRESH 2-AKI, REMOVE, TISORB, CYTATION and the COVID-19 registry, including whether clinical evidence supports efficacy and regulatory submissions.
- Cash use, commercial growth, product gross margin, and the extent of potential dilution from remaining equity-raising capacity; also confirm the status and terms of the undrawn $15 million loan commitment.
- The outcome of the German customs review and any resulting assessment, and the company’s progress toward continued European certification under the applicable medical-device rules.
- How concentrated sales remain in Germany and how reimbursement, distributor performance, currency movements and U.S. regulatory status affect future revenue.